Related references
Note: Only part of the references are listed.Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making
Si-Ye Chen et al.
LEUKEMIA (2021)
Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type
Motoko Yamaguchi et al.
BLOOD (2018)
Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study
Ji-Wei Li et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma
Yi-yun Yao et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2017)
Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma
Yi-yun Yao et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2017)
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China
Xin Li et al.
CLINICAL CANCER RESEARCH (2016)
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
Seok Jin Kim et al.
LANCET ONCOLOGY (2016)
Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
Jing-hua Wang et al.
ONCOTARGET (2016)
Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
Jing-hua Wang et al.
ONCOTARGET (2016)
A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
Ningjing Lin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type
Li Yang et al.
MEDICAL ONCOLOGY (2013)
Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients
Liang Wang et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
Motoko Yamaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type
R. Suzuki et al.
ANNALS OF ONCOLOGY (2010)
Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type
Biyun Wang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group
T. M. Kim et al.
ANNALS OF ONCOLOGY (2008)
Nasal NK/T-cell lymphoma: epidemiology and pathogenesis
Katsuyuki Aozasa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study
J Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy - Result of chemotherapy in NK/T-cell lymphoma
BS Kim et al.
ACTA ONCOLOGICA (2003)
Share Paper
